Centre National De La Recherche Scientifique

Ureka Sarl

Immupharma France Sa

Biomerieux Sa

UniversitÉde Strasbourg

Elro Pharma Sarl

Neomps

Immupharma Sa

Elro Pharma

Gilles Guichard

Jean-Paul Briand

Robert H Zimmer

Juliette Fremaux

Sebastien Goudreau

Ara G Hovanessian

Sylviane Muller

Vincent Semetey

Elisa Rodriguez, Legal Representative

Marie-Christine Galas-Rodriguez, Legal Representative

Pierre Rodriguez, Legal Representative

Jean Paul Briand

Romain Rodriguez, Legal Representative

Claire Venin

Jose P Courty

Fanny Sylvie Michele Monneaux

Aude Violette

Laura Mauran

Yamina Hamma

Johan Hoebeke

Laurent Renia

José Courty

Gersande R Lena

Marc Van Regenmortel

Gavin William Collie

Robert Zimmer

Sylvie Victorine Lucienne Fournel

Stéphane Bellemin-Laponnaz

Vincent Olieric

Dominique Burnouf

Edith Chardon

Lucile Fischer

Arnaud Salaun

Vincent Diemer

Diane Becart

Marc Regenmortel

Slyviane Muller

Arnaud-Pierre Schaffner

Serge Plaue

Karolina Pulka-Ziach

Caterina Maria Lombardo

Chantal Devin

Annie Lang

Haixang Zhang

Eliette Lallemand

Sêbastien Wieckowski

Nathalie Trouche

Olivier Chaloin

Annick Stote

Jérôme Wagner

Ara Hovanessian

Haixing Zhang

Gersande Lena

The present description relates to peptidomimetic foldamers, and their synthesis. In particular, the description provides peptide-amino urea hybrid peptidomimetic foldamers comprising an alpha amino acid peptide portion and an oligourea portion.

Peptide-oligourea hybrid compounds

The present description provides compositions and methods for producing therapeutic compounds. In another aspect the description provides methods for administering the oligomeric compounds for the treatment and prevention of disease in a mammal. In particular, the present disclosure relates to medicaments comprising various novel oligomeric compounds and pharmaceutically acceptable salts thereof. The compounds of the present disclosure may optionally be administered with at least one of a pharmaceutically acceptable excipient, additional pharmacologically active agent or a combination thereof.

Peptide-oligourea foldamer compounds and methods of their use

The present disclosure relates to a pro-drug peptide, or a salt thereof, having improvement for at least one biological property relative to a parent peptide or peptidomimetic, wherein the biological property is selected from the group consisting of therapeutic index, stability, solubility, toxicity, adsorption, and pre-systemic metabolism. The pro-drug peptide comprising the following structure: Z-pep, wherein: pep is the parent peptide or peptidomimetic; Z is a sequence of n amino acids, Z is cleaved in vivo releasing pep; n&#x2265;2 amino acids. The present disclosure also relates to methods of making and using the pro-drug peptide of the present disclosure. For example, the present disclosure describes a pro-drug peptide that may be used to prevent, treat, or ameliorate at least one symptom of hypoglycemia or a hypoglycemia-related disease or disorder.

Pro-drug peptide with improved pharmaceutical properties

The present description provides oligourea catalysts, a polar helical oligomeric strands, and methods for catalyzing reactions with polar helical oligomeric strands and oligourea catalysts. In particular, the invention relates to a polar helical oligomeric strand of at least 4 residues selected from the formula (I) and which can be used as a catalyst.

Bioinspired catalysis using oligourea helical foldamers

The present description provides compositions and methods for producing therapeutic oligomeric compounds. In another aspect the description provides methods for administering the oligomeric compounds for the treatment and prevention of disease in a mammal. In particular, the invention relates to medicaments comprising various novel oligomeric compounds and pharmaceutically acceptable salts thereof. The compounds of the invention may optionally be administered with at least one of a pharmaceutically acceptable excipient, additional pharmacologically active agent or a combination thereof.

Peptide-oligourea chimeric compounds and methods of their use

The present description provides compositions and methods for producing therapeutic oligomeric compounds. In another aspect the description provides methods for administering the oligomeric compounds for the treatment and prevention of disease in a mammal. In particular, the disclosure relates to medicaments comprising various novel oligomeric compounds and pharmaceutically acceptable salts thereof. The compounds of the disclosure may optionally be administered with at least one of a pharmaceutically acceptable excipient, additional pharmacologically active agent or a combination thereof.

Foldamer helix bundle-based molecular encapsulation

A method for treating disorders involving deregulation of cell proliferation and/or angiogenesis comprising the administration of an effective amount of a multivalent synthetic compound comprising a support on which at least 3 pseudopeptide units are grafted, said compound being of formula (I).

Use of multivalent synthetic ligands of surface nucleolin for treating cancer or inflammation

The present invention relates to new optically pure compounds displaying an improved anticancer activity compared to previously known complex mixtures of stereoisomers thereof. Such compounds are of formula (I): wherein each X independently represents any amino acid; n is 0 or 1; m is an integer between 0 and 3; k is an integer of at least 3; Psi is a reduced bond of formula replacing the peptide amide bond between Lys and Pro; and wherein Lys residues in pseudopeptide units of said compound of formula (I) are either all in L configuration or all in D configuration. A method for preparing such compounds, and therapeutic uses thereof are also provided. The synthetic method involves the selective reduction of the peptide bond between Lys and Pro in a dipeptide intermediate with borane. The therapeutic uses are against cancer, inflammation and for wound healing.

Optically pure compounds for improved therapeutic efficiency

The present invention relates to compounds which bind to the hydrophobic pocket of the &#x3b2; clamp, i.e., to the surface of the &#x3b2; ring with which said protein interacts with other proteins of the bacterial replication complex during DNA replication. These compounds are derived from the acetylated peptide AcQLDLF (P6) to improve their affinity to their target.

Compounds binding to the bacterial beta ring

Described is a process for preparing platinum-carbene complexes.

Process for preparing platinum-carbene complexes

Derivatives of the peptide corresponding to the sequence RIHMVYSKRSGKPRGYAFIEY (SEQ ID NO: 1), pharmaceutical compositions, and methods of use thereof are provided.

Phosphorylated derivatives of a U1-70K peptide and their use in the treatment of autoimmune pathologies

A compound of formula (I) is described, wherein Y represents a macrocycle, the ring of which has 9 to 36 atoms, and is functionalized by three amine or COOH functions; Rrepresents a group of formula H&#x2014;X&#x2014;X&#x2014;X&#x2014;X&#x2014;X&#x2014;(X)&#x2014;, i represents 0 or 1, Xis in particular lysine, arginine, or ornithine residues, Xis in particular glycine, asparagine, L-proline or D-proline residues, Xand Xare in particular tyrosine, phenylalanine or 3-nitrotyrosine residues, Xand Xare in particular amino acid residues: NH&#x2014;(CH)&#x2014;COOH, n ranging from 1 to 10, or NH&#x2014;(CH&#x2014;CH&#x2014;O)&#x2014;CHCHCOOH, m ranging from 3 to 6, provided that at least one of the amino acid residues X, X, Xand Xis different from the corresponding amino acid in the sequence of the natural CD40Lys-Gly-Tyr-Tyrfragment(SEQ ID NO: 1).

Multimeric CD40 ligands, method for preparing same and use thereof for preparing drugs

The present invention relates to compositions and methods for producing therapeutic oligomeric compounds. In one aspect the invention relates to methods for administering the oligomeric compounds for the treatment and prevention of disease, for example, a fungal infection, bacterial infection, or cancer, in a mammal. In particular, the invention relates to medicaments comprising various novel oligomeric compounds and pharmaceutically acceptable salts thereof. The compounds of the invention may optionally be administered with at least one of a pharmaceutically acceptable excipient, pharmacologically active agent or a combination thereof.

Hybrid oligomers, their preparation process and pharmaceutical compositions containing them

Growing community of inventors

Wolfisheim, France

Gilles Guichard